Hussman Strategic Advisors Inc. Acquires 31,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hussman Strategic Advisors Inc. boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 75.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 73,500 shares of the biopharmaceutical company’s stock after acquiring an additional 31,500 shares during the period. Halozyme Therapeutics accounts for 1.0% of Hussman Strategic Advisors Inc.’s holdings, making the stock its 12th biggest position. Hussman Strategic Advisors Inc. owned about 0.06% of Halozyme Therapeutics worth $3,514,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Private Advisor Group LLC raised its position in shares of Halozyme Therapeutics by 23.8% in the fourth quarter. Private Advisor Group LLC now owns 29,908 shares of the biopharmaceutical company’s stock valued at $1,430,000 after purchasing an additional 5,745 shares during the period. Convergence Investment Partners LLC grew its stake in Halozyme Therapeutics by 25.9% in the 4th quarter. Convergence Investment Partners LLC now owns 34,713 shares of the biopharmaceutical company’s stock valued at $1,660,000 after buying an additional 7,151 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics in the 4th quarter valued at about $69,000. State of New Jersey Common Pension Fund D raised its holdings in Halozyme Therapeutics by 0.6% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock valued at $2,279,000 after acquiring an additional 302 shares during the period. Finally, Sheaff Brock Investment Advisors LLC lifted its position in Halozyme Therapeutics by 8.8% during the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 7,747 shares of the biopharmaceutical company’s stock worth $370,000 after acquiring an additional 629 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 0.2 %

HALO opened at $57.77 on Thursday. The stock has a market capitalization of $7.35 billion, a price-to-earnings ratio of 19.13, a P/E/G ratio of 0.44 and a beta of 1.25. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a twelve month low of $35.50 and a twelve month high of $65.53. The company has a 50-day simple moving average of $53.07 and a 200 day simple moving average of $54.56.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. Analysts predict that Halozyme Therapeutics, Inc. will post 3.87 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, HC Wainwright raised their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.